The overarching goal of this project is to further improve the differential diagnosis of bvFTD and its underlying neuropathologies in the individual patient, addressing practical limitations to diagnosis both in the clinic and in clinical research settings. Despite substantial advances over the last decades in the clinical and bench science of bvFTD, there are still impediments to progress in this area. First, though in a research setting we have become expert at differentiating bvFTD from various amnestic and non-amnestic variants of AD, bvFTD and AD are still routinely mistaken for each other in both primary and tertiary care centers, demonstrating that community providers still need practical, clinically realistic approaches to differentiating bvFTD and AD. To this end, we will develop a brief, targeted clinical evaluation that is sensitive and specific for the clinical diagnosis of bvFTD versus AD. Second, identification of the molecule responsible for the bvFTD syndrome in an individual patient -- tau, TDP43, or FUS ? remains challenging, even in a research environment where advanced diagnostic tools are available. Thus we will study novel biomarkers such as tau imaging, CSF biomarkers, DNA polymorphisms and RNA expression patterns for their value for in-vivo separation of the bvFTD molecular subtypes. Finally, in both community settings and expert FTD centers, bvFTD and primary mood disorders (MD) such as major depressive disorder (MDD) and bipolar affective disorder (BD) are frequently mistaken for each other. Direct comparison is needed to guide their differentiation, thus we will systematically examine groups of MDD and BD patients with a comprehensive set of neurologic measures and compare them to our bvFTD patients. This will also be an opportunity to explore the clinical presentations of the subset of MD patients in whom biomarkers of neurodegeneration are found. To accomplish our goals, we propose the following aims and activities:
AIM 1 : Identify a set of measures that can discriminate bvFTD from AD at a high level of accuracy and combine them into a brief clinical assessment protocol that could realistically be adopted in clinic. The clinical, imaging, and laboratory data collected in the previous 14 years of this PPG will be analyzed and a standardized clinical battery will be developed that is sensitive to the diagnosis of bvFTD and to the separation of bvFTD from AD and from healthy older controls. Over the next four years this battery will be validated prospectively, using a tiered approach to model cut-points where shifts in sensitivity/specificity occur with the addition of specific clinical tests that incur additional financial and time costs.
AIM 2 : We will examine the benefit of more recently developed biomarker approaches to diagnosis in our bvFTD patients to determine which measures best segregate the molecular subtypes of bvFTD.
AIM 3 : Comprehensively evaluate patients with MD (MDD and BD), matched by age (40-70 years) to our bvFTD patients, to identify features differentiating bvFTD from MD.
AIM 4 : Determine the frequency of neurodegenerative biomarkers in MD patients and evaluate clinical differences in biomarker positive MD patients.
Despite advances in the last decade, there are still impediments to early and precise differential diagnosis of behavioral variant frontotemporal dementia (bvFTD) in the individual patient. Project 4 is designed to address current limitations to diagnosis both in the clinic and in research settings, because new disease-modifying therapies are moving toward the clinic. The goal of this project is to refine the clinical diagnosis of bvFTD versus Alzheimer's disease and mood disorders, including major depressive disorder and bipolar affective disorder, as well as to improve the in-vivo prediction of neuropathological molecule.
| Miller, Zachary A; Rosenberg, Lynne; Santos-Santos, Miguel A et al. (2018) Prevalence of Mathematical and Visuospatial Learning Disabilities in Patients With Posterior Cortical Atrophy. JAMA Neurol 75:728-737 |
| Rojas, Julio C; Stephens, Melanie L; Rabinovici, Gil D et al. (2018) Multiproteinopathy, neurodegeneration and old age: a case study. Neurocase 24:1-6 |
| Dijkstra, Anke A; Lin, Li-Chun; Nana, Alissa L et al. (2018) Von Economo Neurons and Fork Cells: A Neurochemical Signature Linked to Monoaminergic Function. Cereb Cortex 28:131-144 |
| Mok, Sue-Ann; Condello, Carlo; Freilich, Rebecca et al. (2018) Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. Nat Struct Mol Biol 25:384-393 |
| Erkkinen, Michael G; Zúñiga, Raquel Gutiérrez; Pardo, Cristóbal Carnero et al. (2018) Artistic Renaissance in Frontotemporal Dementia. JAMA 319:1304-1306 |
| Schneider, Raphael; McKeever, Paul; Kim, TaeHyung et al. (2018) Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study. J Neurol Neurosurg Psychiatry 89:851-858 |
| Ljubenkov, Peter A; Staffaroni, Adam M; Rojas, Julio C et al. (2018) Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory. Ann Clin Transl Neurol 5:1250-1263 |
| La Joie, Renaud; Bejanin, Alexandre; Fagan, Anne M et al. (2018) Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90:e282-e290 |
| Kim, Eun-Joo; Brown, Jesse A; Deng, Jersey et al. (2018) Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series. J Neurol 265:2960-2971 |
| Henry, Maya L; Hubbard, H Isabel; Grasso, Stephanie M et al. (2018) Retraining speech production and fluency in non-fluent/agrammatic primary progressive aphasia. Brain 141:1799-1814 |
Showing the most recent 10 out of 607 publications
